Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Procaps Gr Q3 Sales $110.00M

Procaps Gr (NASDAQ:PROC) reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $123.90 million by 11.22 percent.

byMichael Horton

November 14, 2022

1 minute read

Procaps Gr (NASDAQ:PROC) reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $123.90 million by 11.22 percent.

Truist Securities Maintains Buy on Analog Devices, Raises Price Target to $203

By Benzinga Newsdesk

Today, 6:58 PM

Truist Securities analyst William Stein maintains Analog Devices (NASDAQ:ADI) with a Buy and raises the price target from $194 to $203.

ADI

The Past Week’s Most Notable Insider Buys: Blackstone, Cricut, Fast Acquisition And More

By Nelson Hem

Today, 6:58 PM

AFIB

Mizuho Maintains Buy on Atmos Energy, Raises Price Target to $110

By Benzinga Newsdesk

Today, 6:58 PM

Mizuho analyst Gabriel Moreen maintains Atmos Energy (NYSE:ATO) with a Buy and raises the price target from $109 to $110.

ATO

Surface Oncology Announces Initiation Of Phase 2 Studies Evaluating SRF388 In Patients With Hepatocellular Carcinoma And Non-Small-Cell Lung Cancer

By Benzinga Newsdesk

Today, 6:58 PM

Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients

SURF

Procaps Gr Q3 Sales $110.00M

Related Posts

Truist Securities Maintains Buy on Analog Devices, Raises Price Target to $203

The Past Week’s Most Notable Insider Buys: Blackstone, Cricut, Fast Acquisition And More

Mizuho Maintains Buy on Atmos Energy, Raises Price Target to $110

Surface Oncology Announces Initiation Of Phase 2 Studies Evaluating SRF388 In Patients With Hepatocellular Carcinoma And Non-Small-Cell Lung Cancer